Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01557582 · ClinicalTrials.gov registry record · NA
Assessmet of Patients With PAH Right Ventricular Volume
A NA study, sponsored by VentriPoint Diagnostics.
- Completed
- Registry status
- NA
- Development phase
- 103
- Enrollment target
NCT01557582: Completed NA study, sponsored by VentriPoint Diagnostics.
NCT01557582 is a NA study that has completed, run by VentriPoint Diagnostics. The registered enrollment target is 103 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01557582, a NA study, has completed, sponsored by VentriPoint Diagnostics.
- COMPLETED
- Registry status
- NA
- Development phase
- 103 participants
- Enrollment target
Study Summary
The primary endpoint of this study is the percent difference between the VentriPoint Medical System (VMS) and cMRI for estimating the end diastolic and end systolic right ventricular volumes (RVEDV and RVESV) in subjects with Pulmonary Arterial Hypertension (PAH). The trial will be defined as positive if the mean VMS-cMRI percent difference is \<10% and \>-10% at a 1-sided 0.025 statistical significance level for RVEDV and for RVESV, with no safety concerns for the VMS procedure.
Primary Outcome
% Difference was measured for right ventricular EDV, ESV and EF.
Interventions
- DEVICE Ventripoint Medical System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-12 |
| Phase | NA |
What the finished NCT01557582 record still lists
NCT01557582 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Ventripoint Medical System is the first listed.
NCT01557582 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01557582 about?
NCT01557582 is a clinical study titled "Assessmet of Patients With PAH Right Ventricular Volume". The primary endpoint of this study is the percent difference between the VentriPoint Medical System (VMS) and cMRI for estimating the end diastolic and end systolic right ventricular volumes (RVEDV and RVESV) in subjects with Pulmonary Arterial Hypertension (PAH). The trial will be defined as positi...
What is the current status of trial NCT01557582?
This trial is currently completed. It is a NA study. The enrollment target is 103 participants. The study started on 2012-04. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01557582?
The interventions under investigation include: Ventripoint Medical System (DEVICE).
Who is sponsoring clinical trial NCT01557582?
This trial is sponsored by VentriPoint Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01557582's enrollment target sits among peer trials
103 837th of 2000 higher than 1,164 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia